{"id":655719,"date":"2023-06-15T10:02:01","date_gmt":"2023-06-15T10:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655719"},"modified":"2023-06-15T10:02:01","modified_gmt":"2023-06-15T10:02:01","slug":"communityacquired-bacterial-pneumonia-cabp-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-key-companies-shionogi-eagle-pharmaceutical","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/communityacquired-bacterial-pneumonia-cabp-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-key-companies-shionogi-eagle-pharmaceutical_655719.html","title":{"rendered":"Community-Acquired Bacterial Pneumonia (CABP) Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Key Companies – Shionogi, Eagle Pharmaceutical"},"content":{"rendered":"
\n
\"Community-Acquired<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Community-Acquired Bacterial Pneumonia market size in the seven major markets was found to be USD 2,616 million in 2022. As per DelveInsight, the Community-Acquired Bacterial Pneumonia Market is anticipated to evolve immensely in the coming years owing to the launch of upcoming therapies, the rise in healthcare spending across the world, and the increased patient pool in the 7MM. Some of the key players in the market include Combioxin, BioAegis Therapeutics, Biotest, Tigenix, and others.<\/div>\n

DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Community-Acquired Bacterial Pneumonia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Community-Acquired Bacterial Pneumonia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Community-Acquired Bacterial Pneumonia treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Community-Acquired Bacterial Pneumonia: An Overview<\/strong><\/p>\n

Community-Acquired Bacterial Pneumonia (CABP) is defined as an acute bacterial infection of the pulmonary parenchyma associated with chest pain, cough, sputum production, difficulty breathing, chills, rigors, fever, or hypotension and is accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph.<\/p>\n

Common typical bacterial pathogens that cause CABP include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. Atypical bacterial pathogens such as Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila also cause CABP.<\/p>\n

CABP symptoms include shortness of breath, coughing, heavy sputum, fever and chills, chest pain that is worse when you breathe or cough, and upper belly (abdomen) pain with nausea, vomiting, or diarrhea. Diagnosis includes several tests: Chest X-ray, which often confirms the diagnosis, blood tests for infection and oxygen status of blood, blood culture tests, and sputum tests.<\/p>\n

Community-Acquired Bacterial Pneumonia Market Key Facts<\/strong><\/p>\n